WO2026022525 - PERSONALIZED CANCER VACCINE COMPOSITION WITH ENHANCED CLONAL COVERAGE
National phase entry is expected:
Publication Number
WO/2026/022525
Publication Date
29.01.2026
International Application No.
PCT/IB2025/052664
International Filing Date
13.03.2025
Title **
[English]
PERSONALIZED CANCER VACCINE COMPOSITION WITH ENHANCED CLONAL COVERAGE
[French]
COMPOSITION DE VACCIN CONTRE LE CANCER PERSONNALISÉ À COUVERTURE CLONALE AMÉLIORÉE
Applicants **
NEC LABORATORIES EUROPE GMBH
Inventors
MOESCH, Anja
EGGERT MARTÍNEZ, Mariana
LEPRI, Marco
AL-QASSEM, Israa
Priority Data
24190023.2
22.07.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2026 | |
| EPO | Filing, Examination, Granting | 8107 | |
| Japan | Filing, Examination, Granting | 2154 | |
| South Korea | Filing, Examination, Granting | 2066 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
19,093
Contact Us
Abstract[English]
A method for machine learning-based design of a vaccine composition for cancer treatment includes determining, based on mutational signatures and using a probabilistic graphical model, a set of clones associated with a collection of patient-specific tumor cells, the mutational signatures having been generated from bulk sequencing data based on a plurality of mutations occurring in tumor cells. Each clone is associated with a subset of the mutations, each clone is predicted to occur at a corresponding frequency, and genetic features are assigned to each clone based on the corresponding frequency. The vaccine composition associated with the patient-specific tumor cells is generated based on the determined set of clones. The method can be applied to use cases in medical Al and healthcare, such as for vaccine design and production, and to support or optimize decision making.[French]
Selon l’invention, un procédé conçu pour la conception par apprentissage automatique d'une composition vaccinale destinée à traiter le cancer consiste à déterminer, sur la base de signatures mutationnelles et à l'aide d'un modèle graphique probabiliste, un ensemble de clones associés à une collection de cellules tumorales spécifiques au patient, les signatures mutationnelles ayant été générées à partir de données de séquençage en vrac sur la base d'une pluralité de mutations survenues dans des cellules tumorales. Chaque clone est associé à un sous-ensemble des mutations, pour chaque clone il est prédit une fréquence d’occurrence correspondante, et des caractéristiques génétiques sont attribuées à chaque clone sur la base de la fréquence correspondante. La composition vaccinale associée aux cellules tumorales spécifiques au patient est générée sur la base de l'ensemble déterminé de clones. Le procédé peut être appliqué à des cas d'utilisation dans le domaine médical utilisant l’IA et les soins de santé, par exemple pour concevoir et produire des vaccins, et pour prendre en charge ou optimiser la prise de décision.